We are delighted to be featured in the latest issue of VentureCapital Magazine, which spotlights the Dresden region as a high-performance hub for key players and innovators in radiopharmaceutical innovation. ROTOP Pharmaka is recognized as a leading manufacturer of radiopharmaceuticals, including an iodine-123 compound used in Parkinson’s diagnostics. The article also emphasizes the strong
RoTecPSMA® Approved in Switzerland – Expanding Access to Advanced Prostate Cancer Diagnostics We are delighted to announce that RoTecPSMA® has received marketing authorization in Switzerland, marking another important milestone in the European rollout of this innovative diagnostic solution. This approval, achieved in close collaboration with our trusted partner and marketing authorization holder medeo AG,
Team ROTOP is back from SNMMI 2025 in New Orleans and feels energized by the global momentum in radiopharmaceuticals. Team ROTOP - Jens Junker, Felix Roschke, Thomas Gottlieb and Tanmaya Joshi - just returned from SNMMI 2025 in New Orleans. This year, the event brought together nearly 8,000 professionals from across the nuclear medicine and radiopharmaceutical
First marketing authorization for RoTecPSMA® We are thrilled to announce that RoTecPSMA® has been approved in the United Kingdom! RoTecPSMA® is a technetium-99m cold kit for SPECT imaging of prostate cancer patients and the first PSMA-SPECT tracer approved in a European country. It marks a significant step forward in closing a gap in patient care,
Andrew Varghese, President USA ROTOP Pharmaka GmbH ROTOP Pharmaka GmbH is pleased to announce new investments secured from GENUI & SHS Capital along with the appointment of Andrew Varghese as its new President of ROTOP USA. Founded in 2000 and based in Dresden-Rossendorf, ROTOP is a leading manufacturer of radiopharmaceutical products. With the
Saxon radiopharmacy network nukliD® strengthens international visibility Today, Thursday 16 January 2025, leading German and international players in the field of radiopharmacy from Saxony agree to intensify their collaboration. The aim of the partners from the fields of research, industry and cluster management is to develop radiopharmacy in Saxony into a centre of innovation and
Healthcare Specialists GENUI and SHS Capital jointly invest in ROTOP, a leading manufacturer and CDMO of radiopharmaceuticals GENUI and SHS Capital are jointly investing in the German company ROTOP Pharmaka GmbH, a provider of development and manufacturing capacities for radiodiagnostics and radiotherapeutics. The objective of the growth investment is to significantly expand ROTOP's production
Auf über 15.000 qm werden zukünftig in Dresden-Rossendorf Forschungs- und Produktionsstätten für die Entwicklung radiopharmazeutischer Innovationen etabliert. Der Fokus liegt dabei auf Dienstleistungen zur Auftragsentwicklung/ -herstellung (CDMO) für klinische Studien, sowie auf der kommerziellen cGMP-Produktion von radiopharmazeutischen Arzneimitteln in den Bereichen Diagnostik und Therapie von Krebserkrankungen. Die Entscheidung für den Neubau ist das Ergebnis
Die besinnliche Zeit des Jahres ist angebrochen, und wir möchten diese Gelegenheit nutzen, uns bei Ihnen für das entgegengebrachte Vertrauen zu bedanken. Die Weihnachtszeit erinnert uns an die Wichtigkeit von Sicherheit und Gesundheit - Werte, die uns in der Medizin täglich begleiten. Darum spenden wir in diesem Jahr einen Betrag in Höhe von 10.000
Contact
ROTOP Pharmaka GmbH
Bautzner Landstraße 400
01328 Dresden
GERMANY
Phone: +49 (0) 351 26 310 100
Email: info@rotop-pharmaka.de
Social Media